Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849043 | 0.88 | PIM1 (0.53) | ASIC3PIM1CNR1CCR1CCR5 | |
| SCHEMBL15947898 | 0.85 | PIM1 (0.57) | PIM1SMN1; SMN2KMONPC1 | |
| Hydrochloric Acid SCHEMBL15659071 | 0.83 | PIM1 (0.55) | PIM1SMN1; SMN2KMONPC1 | |
| SCHEMBL31074836 | 0.83 | CCR1 (0.46) | ASIC3PIM1CCR1CCR5CCR8 | |
| SCHEMBL31074875 | 0.82 | PIM1 (0.48) | ASIC3PIM1CNR1CCR1CCR5 | |
| SCHEMBL827247 | 0.81 | CCR1 (0.48) | PIM1CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL23487646 | 0.80 | MAP4K4 (0.62) | ASIC3PIM1CNR1ALDH1A1NPC1 | |
| SCHEMBL19786689 | 0.80 | CYP2A6 (0.64) | PIM1ALDH1A1HSP90AA1KMO | |
| SCHEMBL30501156 | 0.80 | MAP4K4 (0.62) | ASIC3PIM1CNR1ALDH1A1NPC1 | |
| SCHEMBL18603218 | 0.80 | MAP4K4 (0.62) | ASIC3PIM1CNR1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-12439813-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPRATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12435102-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-12127470-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240254139-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-08-01 | — | — | US | disclosed |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117881677-A | Fused isoxazolyl compounds as KAT6Aw inhibitors | 奥瑞基尼肿瘤有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4341259-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | Aurigene Oncology Limited (IN) | 2024-03-27 | — | — | EP | disclosed |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| CN-1473161-A | Pyrazole compounds as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-02-04 | — | — | CN | disclosed |
| CN-1469874-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-01-21 | — | — | CN | disclosed |
| CN-1469875-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-01-21 | — | — | CN | disclosed |
| EP-1318814-A2 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1317452-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022608-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022602-A2 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | ASIC3 3658/4885PIM1 945/4885CNR1 863/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | ASIC3 4871/4885PIM1 3686/4885CNR1 804/4885 |
| US-12439813-B2 | Organic electroluminescent materials and devices | OCIAD2, DRD2, OPRD1 | ASIC3 2676/4885PIM1 4325/4885CNR1 615/4885 |
| US-12435102-B2 | Organic electroluminescent materials and devices | OXER1, OCIAD1, OCIAD2 | ASIC3 669/4885PIM1 3829/4885CNR1 2582/4885 |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | ASIC3 3658/4885PIM1 945/4885CNR1 863/4885 |
| US-12127470-B2 | Organic electroluminescent materials and devices | SOD1, CLTB, L1CAM | ASIC3 1471/4885PIM1 2899/4885CNR1 3084/4885 |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | ASIC3 3658/4885PIM1 945/4885CNR1 863/4885 |
| US-20240254139-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | KAT6A, KAT6B, KAT2A | ASIC3 2704/4885PIM1 2588/4885CNR1 4624/4885 |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | ASIC3 3658/4885PIM1 945/4885CNR1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.